LoQus23 Therapeutics
LoQus23 Therapeutics is a biotechnology company developing small molecule drugs to treat Huntington's Disease and other triplet repeat expansion diseases. Their approach aims to stop DNA instability and slow neurodegeneration. Their lead program, a potent allosteric small molecule MSH3 inhibitor, is expected to enter the clinic in 2026.
Funding Round: Series A
Funding Amount: £35M
Date: 18-Feb-2025
Investors: Forbion, SV Health Investors' Dementia Discovery Fund, Novartis Venture Fund
Markets: Biotech
HQ: Cambridge, England, United Kingdom
Founded: 2019
Website: https://loqus23.com/
LinkedIn: https://uk.linkedin.com/company/loqus23-therapeutics-ltd
Twitter: https://twitter.com/loqus23
Crunchbase: https://www.crunchbase.com/organization/loqus23-therapeutics
Leave a Comment
Comments
No comments yet.